{"protocolSection":{"identificationModule":{"nctId":"NCT02087423","orgStudyIdInfo":{"id":"D4191C00003"},"secondaryIdInfos":[{"id":"2013-005427-16","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","officialTitle":"A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen","acronym":"ATLANTIC"},"statusModule":{"statusVerifiedDate":"2025-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-02-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-06-03","type":"ACTUAL"},"completionDateStruct":{"date":"2025-03-26","type":"ACTUAL"},"studyFirstSubmitDate":"2014-03-04","studyFirstSubmitQcDate":"2014-03-13","studyFirstPostDateStruct":{"date":"2014-03-14","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-06-03","resultsFirstSubmitQcDate":"2017-12-04","resultsFirstPostDateStruct":{"date":"2018-01-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-04-22","lastUpdatePostDateStruct":{"date":"2025-04-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability","detailedDescription":"This study is designed to investigate the efficacy, safety, tolerability of a new drug, MEDI4736 (Durvalumab), in patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer. MEDI4736 will be investigated in patients who have received at least two prior treatment regimens including one platinum-based chemotherapy"},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Locally advanced, metastatic, Non-Small Cell Lung Cancer, MEDI4736, Durvalumab, PD-L1"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":446,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MEDI4736","type":"EXPERIMENTAL","description":"see below","interventionNames":["Drug: MEDI4736"]}],"interventions":[{"type":"DRUG","name":"MEDI4736","description":"MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.","armGroupLabels":["MEDI4736"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"Patients commenced treatment with durvalumab on Day 1 and continued on a Q2W schedule for a maximum of 12 months. Tumor assessments using computed tomography / magnetic resonance imaging were performed every 8 weeks. Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) measurements as given by the Independent Central Review (ICR) were used to derive the primary variable of ORR .","timeFrame":"Responses recorded during initial 12 month treatment period (up to primary analysis DCO)"}],"secondaryOutcomes":[{"measure":"Time to Response (TTR)","description":"TTR (per RECIST 1.1 as assessed by the ICR) is defined as the time from the date of first dose until the date of first documented response (which is subsequently confirmed). TTR was only analyzed for Cohort 2.","timeFrame":"Responses recorded during initial 12 month treatment period (up to primary analysis DCO)"},{"measure":"Duration of Response (DoR)","description":"DoR (per RECIST 1.1 as assessed by the ICR) was defined as the time from the date of first documented response (which was subsequently confirmed) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). DoR was only analyzed for Cohort 2. Cohort 2: Median DoR was 12.3 months in the PD-L1 high (TC\\>=25%) group at DCO (Q3 was NR). Of the 7 evaluable patients, the median DoR was not reached in the PD-L1 low/neg group (TC \\<25%); therefore the DoR \"number of participants analyzed\" field has been entered as \"0\" and the DoR results field has been left blank.","timeFrame":"Time from response to progression, death, or last assessment (up to approximately 2 years 3 months for the primary analysis DCO)"},{"measure":"Overall Survival (OS)","description":"OS was defined as the time from the date of first dose until death due to any cause (ie, date of death or censoring - date of first dose + 1). Results are reported as median OS, calculated using the Kaplan-Meier methodology.","timeFrame":"From date of first treatment until final DCO (up to approximately 3 years 8 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged at least 18 years.\n* Documented evidence of NSCLC (stage IIIB/IV disease)\n* Disease progression or recurrence after both a platinum-based chemotherapy and at least 1 additional regimen for treatment of NSCLC\n* World Health Organisation (WHO) Performance Status of 0 or 1\n* Estimated life expectancy of more than 12 weeks\n* Patient's tumour sample must be PD-L1 positive (≥25%of tumour cells with membrane staining (Cohort 1 and 2) or PD-L1 positive with ≥90% of tumour cells with membrane staining (Cohort 3))\n\nExclusion Criteria:\n\n* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody\n* Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids).\n* Active or prior autoimmune disease or history of immunodeficiency\n* Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.\n* Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.\n* Any unresolved toxicity CTCAE \\>Grade 2 from previous anti-cancer therapy.\n* Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \\>Grade 1\n* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Phillip Dennis, MD, PhD","affiliation":"AstraZeneca","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Goodyear","state":"Arizona","zip":"85338","country":"United States","geoPoint":{"lat":33.43532,"lon":-112.35821}},{"facility":"Research Site","city":"Santa Rosa","state":"California","zip":"95403","country":"United States","geoPoint":{"lat":38.44047,"lon":-122.71443}},{"facility":"Research Site","city":"New Haven","state":"Connecticut","zip":"06511","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Research Site","city":"Port Saint Lucie","state":"Florida","zip":"34952","country":"United States","geoPoint":{"lat":27.29393,"lon":-80.35033}},{"facility":"Research Site","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Research Site","city":"Lawrenceville","state":"Georgia","zip":"30046","country":"United States","geoPoint":{"lat":33.95621,"lon":-83.98796}},{"facility":"Research Site","city":"Waterloo","state":"Iowa","zip":"50701","country":"United States","geoPoint":{"lat":42.49276,"lon":-92.34296}},{"facility":"Research Site","city":"Topeka","state":"Kansas","zip":"66606","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"Research Site","city":"Bethesda","state":"Maryland","zip":"20817","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}},{"facility":"Research Site","city":"Burlington","state":"Massachusetts","zip":"01803","country":"United States","geoPoint":{"lat":42.50482,"lon":-71.19561}},{"facility":"Research Site","city":"Worcester","state":"Massachusetts","zip":"01608","country":"United States","geoPoint":{"lat":42.26259,"lon":-71.80229}},{"facility":"Research Site","city":"Saint Louis Park","state":"Minnesota","zip":"55426","country":"United States","geoPoint":{"lat":44.9483,"lon":-93.34801}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10011","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"The Bronx","state":"New York","zip":"10461","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Research Site","city":"Huntersville","state":"North Carolina","zip":"28078","country":"United States","geoPoint":{"lat":35.41069,"lon":-80.84285}},{"facility":"Research Site","city":"Bismarck","state":"North Dakota","zip":"58501","country":"United States","geoPoint":{"lat":46.80833,"lon":-100.78374}},{"facility":"Research Site","city":"Fargo","state":"North Dakota","zip":"58102","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"Research Site","city":"Blue Ash","state":"Ohio","zip":"45242","country":"United States","geoPoint":{"lat":39.232,"lon":-84.37827}},{"facility":"Research Site","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"Research Site","city":"Middletown","state":"Ohio","zip":"45042","country":"United States","geoPoint":{"lat":39.51506,"lon":-84.39828}},{"facility":"Research Site","city":"Chattanooga","state":"Tennessee","zip":"37404","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Research Site","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Research Site","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Research Site","city":"Spokane","state":"Washington","zip":"99208","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Research Site","city":"Wenatchee","state":"Washington","zip":"98801","country":"United States","geoPoint":{"lat":47.42346,"lon":-120.31035}},{"facility":"Research Site","city":"Vienna","zip":"1145","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Research Site","city":"Brussels","zip":"1000","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Research Site","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Research Site","city":"Gilly","zip":"6060","country":"Belgium","geoPoint":{"lat":50.42449,"lon":4.4789}},{"facility":"Research Site","city":"Kortrijk","zip":"8500","country":"Belgium","geoPoint":{"lat":50.82803,"lon":3.26487}},{"facility":"Research Site","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"Research Site","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Research Site","city":"Hamilton","state":"Ontario","zip":"L8V 5C2","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Research Site","city":"London","state":"Ontario","zip":"N6A 4L6","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Research Site","city":"Ottawa","state":"Ontario","zip":"K1H 8L6","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"Research Site","city":"Toronto","state":"Ontario","zip":"M4N 3M5","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Research Site","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Research Site","city":"Regina","state":"Saskatchewan","zip":"S4T 7T1","country":"Canada","geoPoint":{"lat":50.45008,"lon":-104.6178}},{"facility":"Research Site","city":"Brno","zip":"656 53","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Research Site","city":"Prague","zip":"14059","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Research Site","city":"Prague","zip":"150 06","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Research Site","city":"Prague","zip":"180 81","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Research Site","city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Research Site","city":"Brest","zip":"29609","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"Research Site","city":"Créteil","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Research Site","city":"Dijon","zip":"21034","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"facility":"Research Site","city":"Le Mans","zip":"72015","country":"France","geoPoint":{"lat":48.0021,"lon":0.20251}},{"facility":"Research Site","city":"Marseille","zip":"13015","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Research Site","city":"Pessac","zip":"33600","country":"France","geoPoint":{"lat":44.80565,"lon":-0.6324}},{"facility":"Research Site","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Research Site","city":"Saint-Herblain","zip":"44805","country":"France","geoPoint":{"lat":47.21154,"lon":-1.651}},{"facility":"Research Site","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Research Site","city":"Berlin","zip":"10967","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Research Site","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Research Site","city":"Borstel","zip":"23845","country":"Germany","geoPoint":{"lat":52.67034,"lon":8.96896}},{"facility":"Research Site","city":"Cologne","zip":"50924","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Research Site","city":"Dortmund","zip":"44263","country":"Germany","geoPoint":{"lat":51.51494,"lon":7.466}},{"facility":"Research Site","city":"Frankfurt am Main","zip":"60590","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Research Site","city":"Freiburg im Breisgau","zip":"79106","country":"Germany","geoPoint":{"lat":47.9959,"lon":7.85222}},{"facility":"Research Site","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Research Site","city":"Hamburg","zip":"20251","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Research Site","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Research Site","city":"Budapest","zip":"1083","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Győr","zip":"9024","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"Research Site","city":"Szolnok","zip":"5000","country":"Hungary","geoPoint":{"lat":47.18066,"lon":20.19835}},{"facility":"Research Site","city":"Tatabánya","zip":"2800","country":"Hungary","geoPoint":{"lat":47.59247,"lon":18.38099}},{"facility":"Research Site","city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Research Site","city":"Candiolo","zip":"10060","country":"Italy","geoPoint":{"lat":44.95858,"lon":7.59812}},{"facility":"Research Site","city":"Catania","zip":"95125","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Research Site","city":"Milan","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Monza","zip":"20900","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"Research Site","city":"Orbassano","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Research Site","city":"Perugia","zip":"06132","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Research Site","city":"Pisa","zip":"56124","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"Research Site","city":"Roma","zip":"00144","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Research Site","city":"Rozzano","zip":"20089","country":"Italy","geoPoint":{"lat":45.38193,"lon":9.1559}},{"facility":"Research Site","city":"Akashi-shi","zip":"673-8558","country":"Japan"},{"facility":"Research Site","city":"Bunkyō City","zip":"113-8603","country":"Japan","geoPoint":{"lat":35.5331,"lon":139.4217}},{"facility":"Research Site","city":"Chūōku","zip":"104-0045","country":"Japan","geoPoint":{"lat":33.63867,"lon":130.67068}},{"facility":"Research Site","city":"Habikino-shi","zip":"583-8588","country":"Japan"},{"facility":"Research Site","city":"Hidaka-shi","zip":"350-1298","country":"Japan"},{"facility":"Research Site","city":"Hirakata-shi","zip":"573-1191","country":"Japan"},{"facility":"Research Site","city":"Kashiwa","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.86224,"lon":139.97732}},{"facility":"Research Site","city":"Kitaadachi-gun","zip":"362-0806","country":"Japan"},{"facility":"Research Site","city":"Kobe","zip":"650-0047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Research Site","city":"Kōtoku","zip":"135-8550","country":"Japan","geoPoint":{"lat":42.50417,"lon":143.14297}},{"facility":"Research Site","city":"Kurume-shi","zip":"830-0011","country":"Japan"},{"facility":"Research Site","city":"Nagoya","zip":"460-0001","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Research Site","city":"Natori-shi","zip":"981-1293","country":"Japan","geoPoint":{"lat":38.16667,"lon":140.88333}},{"facility":"Research Site","city":"Osaka","zip":"534-0021","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Research Site","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Research Site","city":"Sakaishi","zip":"591-8555","country":"Japan","geoPoint":{"lat":33.41239,"lon":132.71218}},{"facility":"Research Site","city":"Sayama","zip":"589-8511","country":"Japan","geoPoint":{"lat":34.51685,"lon":135.56298}},{"facility":"Research Site","city":"Sendai","zip":"980-0873","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Research Site","city":"Shinjuku-ku","zip":"160-0023","country":"Japan"},{"facility":"Research Site","city":"Sunto-gun","zip":"411-8777","country":"Japan"},{"facility":"Research Site","city":"Ube-shi","zip":"755-0241","country":"Japan"},{"facility":"Research Site","city":"Yokohama","zip":"236-0051","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Research Site","city":"Yokohama","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Research Site","city":"Cebu City","zip":"6000","country":"Philippines","geoPoint":{"lat":10.31672,"lon":123.89071}},{"facility":"Research Site","city":"Quezon City","zip":"0870","country":"Philippines","geoPoint":{"lat":14.6488,"lon":121.0509}},{"facility":"Research Site","city":"Quezon City","zip":"1100","country":"Philippines","geoPoint":{"lat":14.6488,"lon":121.0509}},{"facility":"Research Site","city":"Quezon City","zip":"1101","country":"Philippines","geoPoint":{"lat":14.6488,"lon":121.0509}},{"facility":"Research Site","city":"Gdansk","zip":"80-952","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Research Site","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Singapore","zip":"119228","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Research Site","city":"Singapore","zip":"169610","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Research Site","city":"Singapore","zip":"308440","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Research Site","city":"Goyang-si","zip":"10408","country":"South Korea","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Research Site","city":"Hwasun-gun","zip":"58128","country":"South Korea"},{"facility":"Research Site","city":"Seongnam-si","zip":"13620","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Research Site","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"152-703","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Barcelona","zip":"08908","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Girona","zip":"17007","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Research Site","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Research Site","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Research Site","city":"Taichung","zip":"40447","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Research Site","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Research Site","city":"Tainan","zip":"704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Research Site","city":"Taipei","zip":"10002","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Research Site","city":"Taipei","zip":"112","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Research Site","city":"Hat Yai","zip":"90110","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}},{"facility":"Research Site","city":"Muang","zip":"50200","country":"Thailand"},{"facility":"Research Site","city":"Edinburgh","zip":"EH4 2XU","country":"United Kingdom","geoPoint":{"lat":55.95206,"lon":-3.19648}},{"facility":"Research Site","city":"London","zip":"EC1A 7BE","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Research Site","city":"Manchester","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Research Site","city":"Stoke-on-Trent","zip":"ST4 6QG","country":"United Kingdom","geoPoint":{"lat":53.00415,"lon":-2.18538}}]},"referencesModule":{"references":[{"pmid":"33319498","type":"DERIVED","citation":"Gavrilov S, Zhudenkov K, Helmlinger G, Dunyak J, Peskov K, Aksenov S. Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab. CPT Pharmacometrics Syst Pharmacol. 2021 Jan;10(1):67-74. doi: 10.1002/psp4.12578. Epub 2020 Dec 21."},{"pmid":"32816849","type":"DERIVED","citation":"Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS, Segal NH, Chaft JE, Hembrough T, Barrett JC, Hellmann MD. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020 Dec;10(12):1842-1853. doi: 10.1158/2159-8290.CD-20-0047. Epub 2020 Aug 14."},{"pmid":"32702570","type":"DERIVED","citation":"Garassino MC, Cho BC, Kim JH, Mazieres J, Vansteenkiste J, Lena H, Jaime JC, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Poole L, Wadsworth C, Dennis PA, Rizvi NA. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer. 2020 Sep;147:137-142. doi: 10.1016/j.lungcan.2020.06.032. Epub 2020 Jun 30."},{"pmid":"31102143","type":"DERIVED","citation":"Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations. Pharmacoeconomics. 2019 Sep;37(9):1129-1138. doi: 10.1007/s40273-019-00806-4."},{"pmid":"29545095","type":"DERIVED","citation":"Garassino MC, Cho BC, Kim JH, Mazieres J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12."}],"seeAlsoLinks":[{"label":"AstraZeneca Cancer Study Locator Service astrazeneca@emergingmed.com 1-877-400-4656","url":"http://www.emergingmed.com"},{"label":"d4191c00003 revised csp 4 Redacted","url":"http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2583&filename=d4191c00003-revised-csp-4_Redacted.pdf"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","infoTypes":["STUDY_PROTOCOL","SAP"],"timeFrame":"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","accessCriteria":"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","url":"https://astrazenecagroup-dt.pharmacm.com/DT/Home"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Patients were enrolled in 3 cohorts. Cohort enrolment was dependent upon epidermal growth factor receptor (EGFR) / anaplastic lymphoma kinase (ALK) status and programmed cell death ligand-1 (PD-L1) expression level (percent of tumor cells \\[TC\\] with membrane staining).","recruitmentDetails":"First patient in: 25 Feb 2014; Last patient in: 28 Dec 2015. Primary Analysis data cut-off (DCO): 03 Jun 2016; Final Analysis DCO: 7 Nov 2017. Patients were treated with durvalumab (10 milligrams \\[mg\\] / kilogram \\[kg\\] every 2 weeks \\[Q2W\\] intravenously \\[iv\\]). 101 sites in 16 countries treated patients in this study.","groups":[{"id":"FG000","title":"Cohort 1 (EGFR/ALK+)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"FG001","title":"Cohort 2","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"FG002","title":"Cohort 3 (TC >= 90%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and prospectively determined to be PD-L1 high (TC \\>=90%)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Treated","numSubjects":"111"},{"groupId":"FG001","comment":"Treated","numSubjects":"265"},{"groupId":"FG002","comment":"Treated","numSubjects":"68"}]},{"type":"Completed 12 Months of Treatment","achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"26"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"111"},{"groupId":"FG001","numSubjects":"265"},{"groupId":"FG002","numSubjects":"68"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"68"},{"groupId":"FG001","numSubjects":"207"},{"groupId":"FG002","numSubjects":"40"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Terminated from study at final DCO","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"36"},{"groupId":"FG002","numSubjects":"25"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Baseline analysis was based on the safety analysis set, defined as all patients who received at least 1 dose of durvalumab and for whom any postdose data were available.","groups":[{"id":"BG000","title":"Cohort 1 (EGFR/ALK+)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"BG001","title":"Cohort 2","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"BG002","title":"Cohort 3 (TC >= 90%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and prospectively determined to be PD-L1 high (TC \\>=90%)."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"265"},{"groupId":"BG002","value":"68"},{"groupId":"BG003","value":"444"}]}],"measures":[{"title":"Age, Categorical","description":"age groups of \\<=18, between 18 and 65, \\>=65,","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"155"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"265"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"179"}]}]}]},{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.0","spread":"11.45"},{"groupId":"BG001","value":"62.0","spread":"9.35"},{"groupId":"BG002","value":"61.0","spread":"10.58"},{"groupId":"BG003","value":"62.0","spread":"10.13"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"202"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"162"},{"groupId":"BG002","value":"39"},{"groupId":"BG003","value":"242"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"212"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"298"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"141"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"27"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"246"},{"groupId":"BG002","value":"66"},{"groupId":"BG003","value":"417"}]}]}]},{"title":"Weight","paramType":"MEDIAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59","spread":"14.15"},{"groupId":"BG001","value":"68","spread":"14.52"},{"groupId":"BG002","value":"66","spread":"15.79"},{"groupId":"BG003","value":"66","spread":"14.93"}]}]}]},{"title":"Weight group","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<70 kg","measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"146"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"267"}]},{"title":"Between 70 and 90 kg","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"145"}]},{"title":">90 kg","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"32"}]}]}]},{"title":"WHO performance status","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"(0) Normal activity","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"150"}]},{"title":"(1) Restricted activity","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"178"},{"groupId":"BG002","value":"49"},{"groupId":"BG003","value":"292"}]},{"title":"(2) In bed <=50% of the time","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]},{"title":"(3) In bed >50% of the time","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"(4) 100% bed ridden","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Primary tumor location","description":"Lung","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"265"},{"groupId":"BG002","value":"68"},{"groupId":"BG003","value":"444"}]}]}]},{"title":"Histology type","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Squamous","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"76"}]},{"title":"Non-squamous","measurements":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"210"},{"groupId":"BG002","value":"48"},{"groupId":"BG003","value":"368"}]}]}]},{"title":"AJCC staging at initial diagnosis","description":"Per tumor, node, metastasis (TNM) staging system as specified by American Joint Committee on Cancer (AJCC). The staging is determined by a number of different parameters and the higher the staging the worse the prognosis for survival.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Stage IA","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}]},{"title":"Stage IB","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}]},{"title":"Stage II","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"Stage IIA","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]},{"title":"Stage IIB","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}]},{"title":"Stage III","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"Stage IIIA","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"27"}]},{"title":"Stage IIIB","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"45"}]},{"title":"Stage IV","measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"208"},{"groupId":"BG002","value":"53"},{"groupId":"BG003","value":"351"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]}]},{"title":"Best response to previous therapy","description":"based on the last therapy received prior to entering the study","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"complete response","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"partial response","measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"88"}]},{"title":"stable disease","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"138"}]},{"title":"progression","measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"178"}]},{"title":"non-evaluable","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"19"}]},{"title":"not applicable","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"20"}]}]}]},{"title":"Time from informed consent to first dose","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=14 days","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"96"}]},{"title":"Between 14 and 21 days","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"110"}]},{"title":"between 21 and 42 days","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"45"},{"groupId":"BG003","value":"221"}]},{"title":"> 42 days","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"17"}]}]}]},{"title":"Overall disease classification","description":"either patient has any metastatic site of disease or has only locally advanced sites of disease","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Metastatic","measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"245"},{"groupId":"BG002","value":"61"},{"groupId":"BG003","value":"408"}]},{"title":"Locally advanced","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"36"}]}]}]},{"title":"PD-L1 expression level","description":"% of tumor cells with membrane staining for PD-L1","paramType":"NUMBER","unitOfMeasure":"Number of patients (per PD-L1 category)","classes":[{"title":"Positive (>=25%)","categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"68"},{"groupId":"BG003","value":"294"}]}]},{"title":"Negative (<25%)","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"125"}]}]},{"title":"Positive (>=90%)","categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"67"},{"groupId":"BG003","value":"186"}]}]},{"title":"<90%","categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"155"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"24"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]},{"title":"Total per cohort","categories":[{"measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"265"},{"groupId":"BG002","value":"68"},{"groupId":"BG003","value":"444"}]}]}]},{"title":"Smoking history","description":"Patients who checked options Cigarettes, Cigarillos, Cigars, Pipe Tobacco, or Tobacco for Smoking are considered smokers.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Non-smoker","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"113"}]},{"title":"Smoker","measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"59"},{"groupId":"BG003","value":"330"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]}]},{"title":"Number of regimens of previous anti-cancer therapy","paramType":"MEDIAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Number of regimens","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3","spread":"2.00"},{"groupId":"BG001","value":"3","spread":"1.38"},{"groupId":"BG002","value":"2","spread":"0.80"},{"groupId":"BG003","value":"3","spread":"1.54"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR)","description":"Patients commenced treatment with durvalumab on Day 1 and continued on a Q2W schedule for a maximum of 12 months. Tumor assessments using computed tomography / magnetic resonance imaging were performed every 8 weeks. Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) measurements as given by the Independent Central Review (ICR) were used to derive the primary variable of ORR .","populationDescription":"The \"Full analysis set \\[FAS\\] - evaluable for response per ICR\" set, included all treated patients who had a baseline tumor assessment and had measurable disease at baseline according to the ICR.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"% of patients evaluable for response","timeFrame":"Responses recorded during initial 12 month treatment period (up to primary analysis DCO)","groups":[{"id":"OG000","title":"Cohort 1 (EGFR/ALK+) PD-L1+ (>=25%)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown. patients with PD-L1 TC\\>=90% are included in this group."},{"id":"OG001","title":"Cohort 1 (EGFR/ALK+) PD-L1+ (<25%)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"OG002","title":"Cohort 2 PD-L1+ (>=25%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown. Patients with PD-L1 TC\\>=90% are included within the PD-L1 high (TC\\>=25%) group."},{"id":"OG003","title":"Cohort 2 PD-L1+ (<25%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"OG004","title":"Cohort 3 (TC>=90%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and prospectively determined to be PD-L1 high (TC\\>=90%)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"146"},{"groupId":"OG003","value":"93"},{"groupId":"OG004","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"5.7","upperLimit":"21.8"},{"groupId":"OG001","value":"3.6","lowerLimit":"0.1","upperLimit":"18.3"},{"groupId":"OG002","value":"16.4","lowerLimit":"10.8","upperLimit":"23.5"},{"groupId":"OG003","value":"7.5","lowerLimit":"3.1","upperLimit":"14.9"},{"groupId":"OG004","value":"30.9","lowerLimit":"20.2","upperLimit":"43.3"}]}]}]},{"type":"SECONDARY","title":"Time to Response (TTR)","description":"TTR (per RECIST 1.1 as assessed by the ICR) is defined as the time from the date of first dose until the date of first documented response (which is subsequently confirmed). TTR was only analyzed for Cohort 2.","populationDescription":"The \"FAS - evaluable for response per ICR\" set for Cohort 2, included all treated patients in Cohort 2 who had a baseline tumor assessment and had measurable disease at baseline according to the ICR.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"Responses recorded during initial 12 month treatment period (up to primary analysis DCO)","groups":[{"id":"OG000","title":"Cohort 1 (EGFR/ALK+) PD-L1+ (>=25%)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown. patients with PD-L1 TC\\>=90% are included in this group."},{"id":"OG001","title":"Cohort 1 (EGFR/ALK+) PD-L1+ (<25%)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"OG002","title":"Cohort 2 PD-L1+ (>=25%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown. Patients with PD-L1 TC\\>=90% are included within the PD-L1 high (TC\\>=25%) group."},{"id":"OG003","title":"Cohort 2 PD-L1+ (<25%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"OG004","title":"Cohort 3 (TC>=90%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and prospectively determined to be PD-L1 high (TC\\>=90%)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"1.9","lowerLimit":"1.6","upperLimit":"16.7"},{"groupId":"OG003","value":"2.1","lowerLimit":"1.7","upperLimit":"13.8"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"DoR (per RECIST 1.1 as assessed by the ICR) was defined as the time from the date of first documented response (which was subsequently confirmed) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). DoR was only analyzed for Cohort 2. Cohort 2: Median DoR was 12.3 months in the PD-L1 high (TC\\>=25%) group at DCO (Q3 was NR). Of the 7 evaluable patients, the median DoR was not reached in the PD-L1 low/neg group (TC \\<25%); therefore the DoR \"number of participants analyzed\" field has been entered as \"0\" and the DoR results field has been left blank.","populationDescription":"The \"FAS - evaluable for response per ICR\" set for Cohort 2, included all treated patients in Cohort 2 who had a baseline tumor assessment and had measurable disease at baseline according to the ICR.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"Months","timeFrame":"Time from response to progression, death, or last assessment (up to approximately 2 years 3 months for the primary analysis DCO)","groups":[{"id":"OG000","title":"Cohort 1 (EGFR/ALK+) PD-L1+ (>=25%)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown. patients with PD-L1 TC\\>=90% are included in this group."},{"id":"OG001","title":"Cohort 1 (EGFR/ALK+) PD-L1+ (<25%)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"OG002","title":"Cohort 2 PD-L1+ (>=25%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown. Patients with PD-L1 TC\\>=90% are included within the PD-L1 high (TC\\>=25%) group."},{"id":"OG003","title":"Cohort 2 PD-L1+ (<25%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"OG004","title":"Cohort 3 (TC>=90%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and prospectively determined to be PD-L1 high (TC\\>=90%)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"12.3","lowerLimit":"7.5","upperLimit":"NA","comment":"75th percentile not reached (NR)"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from the date of first dose until death due to any cause (ie, date of death or censoring - date of first dose + 1). Results are reported as median OS, calculated using the Kaplan-Meier methodology.","populationDescription":"The FAS included all treated patients who had a baseline tumor assessment and had measurable disease at baseline according to the Investigator site assessment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of first treatment until final DCO (up to approximately 3 years 8 months)","groups":[{"id":"OG000","title":"Cohort 1 (EGFR/ALK+) PD-L1+ (>=25%)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown. patients with PD-L1 TC\\>=90% are included in this group."},{"id":"OG001","title":"Cohort 1 (EGFR/ALK+) PD-L1+ (<25%)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"OG002","title":"Cohort 2 PD-L1+ (>=25%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown. Patients with PD-L1 TC\\>=90% are included within the PD-L1 high (TC\\>=25%) group."},{"id":"OG003","title":"Cohort 2 PD-L1+ (<25%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown."},{"id":"OG004","title":"Cohort 3 (TC>=90%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and prospectively determined to be PD-L1 high (TC\\>=90%)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"94"},{"groupId":"OG004","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"6.3","upperLimit":"24.5"},{"groupId":"OG001","value":"9.9","lowerLimit":"4.2","upperLimit":"13.3"},{"groupId":"OG002","value":"10.9","lowerLimit":"8.6","upperLimit":"13.6"},{"groupId":"OG003","value":"9.3","lowerLimit":"5.9","upperLimit":"10.8"},{"groupId":"OG004","value":"13.2","lowerLimit":"5.9","upperLimit":"NA","comment":"The upper limit of 95% confidence interval was not reached for patients in Cohort 3."}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Treatment-emergent adverse events (TEAEs) observed up until 90 days following discontinuation of durvalumab or until the initiation of the first subsequent anticancer therapy following discontinuation of durvalumab (whichever occurred first).","description":"All-Cause Mortality is reported for the overall study period, up to the final DCO. Serious and Other (non-serious) TEAE data is reported for the initial treatment phase (maximum of 12 months of treatment).","eventGroups":[{"id":"EG000","title":"Cohort 1 (EGFR/ALK+)","description":"Consisted of patients who were EGFR/ALK positive and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown.","deathsNumAffected":70,"deathsNumAtRisk":111,"seriousNumAffected":18,"seriousNumAtRisk":111,"otherNumAffected":96,"otherNumAtRisk":111},{"id":"EG001","title":"Cohort 2","description":"Consisted of patients who were EGFR/ALK wild type/unknown and retrospectively or prospectively determined to be PD-L1 high (TC \\>=25%). In addition, the cohort included patients enrolled prior to Amendment 1 who were retrospectively determined to be PD-L1 low/neg (TC \\<25%) or PD-L1 status unknown.","deathsNumAffected":217,"deathsNumAtRisk":265,"seriousNumAffected":77,"seriousNumAtRisk":265,"otherNumAffected":233,"otherNumAtRisk":265},{"id":"EG002","title":"Cohort 3 (TC >=90%)","description":"Consisted of patients who were EGFR/ALK wild type/unknown and prospectively determined to be PD-L1 high (TC \\>=90%).","deathsNumAffected":41,"deathsNumAtRisk":68,"seriousNumAffected":24,"seriousNumAtRisk":68,"otherNumAffected":60,"otherNumAtRisk":68}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":265},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":68}]},{"term":"Haemolytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Hypopituitarism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Hepatic atrophy","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Jaundice cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Ophthalmic herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Intracranial pressure increased","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Ureteric obstruction","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":265},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":68}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Diabetes insipidus","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Oesophageal rupture","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":68}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Bronchitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Campylobacter gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Central nervous system infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Pneumococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Streptococcal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Urine output decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Tumour haemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":111},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":68}]},{"term":"Organising pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":111},{"groupId":"EG001","numEvents":52,"numAffected":43,"numAtRisk":265},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":68}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":111},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":265},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":68}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":111},{"groupId":"EG001","numEvents":24,"numAffected":19,"numAtRisk":265},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":68}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":111},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":265},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":68}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":111},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":111},{"groupId":"EG001","numEvents":45,"numAffected":37,"numAtRisk":265},{"groupId":"EG002","numEvents":19,"numAffected":16,"numAtRisk":68}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":111},{"groupId":"EG001","numEvents":53,"numAffected":39,"numAtRisk":265},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":68}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":111},{"groupId":"EG001","numEvents":57,"numAffected":46,"numAtRisk":265},{"groupId":"EG002","numEvents":15,"numAffected":12,"numAtRisk":68}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":111},{"groupId":"EG001","numEvents":36,"numAffected":27,"numAtRisk":265},{"groupId":"EG002","numEvents":13,"numAffected":10,"numAtRisk":68}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":111},{"groupId":"EG001","numEvents":76,"numAffected":53,"numAtRisk":265},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":68}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":111},{"groupId":"EG001","numEvents":80,"numAffected":69,"numAtRisk":265},{"groupId":"EG002","numEvents":31,"numAffected":20,"numAtRisk":68}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":111},{"groupId":"EG001","numEvents":15,"numAffected":10,"numAtRisk":265},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":68}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":111},{"groupId":"EG001","numEvents":25,"numAffected":25,"numAtRisk":265},{"groupId":"EG002","numEvents":13,"numAffected":9,"numAtRisk":68}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":111},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":265},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":68}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":111},{"groupId":"EG001","numEvents":81,"numAffected":53,"numAtRisk":265},{"groupId":"EG002","numEvents":16,"numAffected":12,"numAtRisk":68}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":111},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":265},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":68}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":111},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":265},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":68}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":111},{"groupId":"EG001","numEvents":19,"numAffected":15,"numAtRisk":265},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":68}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":111},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":265},{"groupId":"EG002","numEvents":18,"numAffected":11,"numAtRisk":68}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":111},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":265},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":68}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":111},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":265},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":68}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":111},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":265},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":68}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":111},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":265},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":68}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":111},{"groupId":"EG001","numEvents":22,"numAffected":22,"numAtRisk":265},{"groupId":"EG002","numEvents":13,"numAffected":13,"numAtRisk":68}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":111},{"groupId":"EG001","numEvents":77,"numAffected":71,"numAtRisk":265},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":68}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":111},{"groupId":"EG001","numEvents":20,"numAffected":14,"numAtRisk":265},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":68}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":111},{"groupId":"EG001","numEvents":25,"numAffected":21,"numAtRisk":265},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":68}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":111},{"groupId":"EG001","numEvents":24,"numAffected":23,"numAtRisk":265},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":68}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":111},{"groupId":"EG001","numEvents":21,"numAffected":16,"numAtRisk":265},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":68}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":111},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":265},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":68}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":111},{"groupId":"EG001","numEvents":21,"numAffected":18,"numAtRisk":265},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":68}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":111},{"groupId":"EG001","numEvents":18,"numAffected":12,"numAtRisk":265},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":68}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":111},{"groupId":"EG001","numEvents":32,"numAffected":26,"numAtRisk":265},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":68}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":111},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":265},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":68}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":111},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":265},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":68}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":26,"numAtRisk":111},{"groupId":"EG001","numEvents":67,"numAffected":56,"numAtRisk":265},{"groupId":"EG002","numEvents":16,"numAffected":13,"numAtRisk":68}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":111},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":265},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":68}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":111},{"groupId":"EG001","numEvents":46,"numAffected":43,"numAtRisk":265},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":68}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":111},{"groupId":"EG001","numEvents":20,"numAffected":14,"numAtRisk":265},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":68}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":111},{"groupId":"EG001","numEvents":23,"numAffected":20,"numAtRisk":265},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":68}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":111},{"groupId":"EG001","numEvents":39,"numAffected":27,"numAtRisk":265},{"groupId":"EG002","numEvents":14,"numAffected":13,"numAtRisk":68}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":111},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":265},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":68}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Phillip Dennis, MD, PhD","organization":"AstraZeneca","email":"ClinicalTrialTransparency@astrazeneca.com","phone":"+1 301 398-5549"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Malaysia"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D009362","term":"Neoplasm Metastasis"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D009385","term":"Neoplastic Processes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"}]}},"hasResults":true}